Department of Basic Areas



Teacher profile

Basic Areas, DEPARTMENT OF BASIC SCIENCIES. Universitat Internacional de Catalunya


Doctor en Ciencias Biológicas - UNIVERSITAT DE BARCELONA
Graduat en Biologia - Universitat de Barcelona
IESE Business School. University of Navarra Madrid, Spain Executive education. Management Development Program. Sponsored by GSK
1997-1998. IE Business School (Instituto de Empresa) Madrid, Spain Executive education. Management Development Program. Sponsored by GSK
1987-1988. USUHS (Uniformed Services University of the Health Sciences) Bethesda, MD Research associate at USUHS. Department of Defense, USA
1985-1987. University of Barcelona. Barcelona, Spain Assistant Professor in the Department of Microbiology and Parasitology of
the Faculty of Pharmacy

Professional experience

2015-present. ABAC Therapeutics CEO and Chief scientific officer
• Led spin-out of the precision antibacterial agents project from Ferrer into start-up ABAC Therapeutics. Promoter of the application of precision medicine to the treatment of infectious diseases, using pathogen-specific and narrow spectrum compounds. Member of the company board
• Defined corporate strategy, business development models and priorities to make the company attractive to investor
• Developed and strategically managed international networks of relationships with key stakeholders, including investors, opinion leaders, and collaboration agreements with CROs and other public and private institutions to nurturing talent, and delivering productivity goals.
• Meetings with regulatory agencies to agree on the development of these novel compounds,
representatives of a new paradigm in the treatment of infectious diseases 2008-2015. Ferrer Laboratories Infectious Diseases Manager Director of Pharmacology, Toxicology and Safety Pharmacology Departments
• Responsible for managing the portfolio, including projects in discovery and development
• Envisioned and executed transformative pipeline, resulting in change of company profile, from a single asset-based company to multi-asset infectious diseases play, with a pipeline that includes additional first-in-class projects
• Assembled and managed cross-functional teams to develop and execute operational and organizational plans for building novel scientific projects, building technology/capability platforms, nurturing talent, and delivering productivity goals
• Led Ozenoxacin (a new non-fluorinated quinolone) from pre-clinical candidate to the market (the compound has been approved recently in 15 European states, Canada and USA). Including meetings with regulatory agencies.
• Implement the logistics for the search of pathogen-specific and narrow spectrum compounds, using novel and more efficient drug discovery strategy, the PasNas platform, developed based on my personal experience. The search for precision antibacterial agents (novel TPP) together with the use of the PasNas algorithm were the origin the embryo of ABAC Therapeutics. 1990-2008. Glaxo, GlaxoWellcome, GlaxoSmithkline (GSK) Director of Drug Discovery Biology
• During the 18 years in GSK have held different positions with increasing degrees of responsibility in the matrix structure
• Recruited into Glaxo Tres Cantos Research Center (first scientist with experience in microbiology and drug discovery) to build the facilities of the biology area and take all measures and actions to make the laboratories operational. Including biosafety laboratories and an animal facility to work with category 3 infectious agents
- Had responsibilities for the design and construction supervision of facilities, collaborating closely with the engineering and construction company, and for the purchase of laboratory equipment
- Coordination, supervision and approval of work procedures (SOPs)
- Recruitment of employees, to build high-performing teams and implement operational logistics between departments in the biology area.
- Head of Radioactive Protection and Biological Protection Officer
• Dedicated developer multicultural work teams, focused on building and running high-performing teams to innovate and deliver on both science- and business-driven milestones
- Led the following scientific units: Microbiology, Parasitology, Cell Biology, Pharmacology, DMPK, Toxicology and Safety Pharmacology, both in vitro and in vivo.
- Attention to teamwork, communication between disciplines, and the streamlining of logistics processes between units to optimize resources and speeding up the processes of discovery and development of new drugs.
- Responsible for driving disruptive innovation and entrepreneurship among team members
As manager of therapeutic area and Project Leader
• As project leader or drug discovery representative, led to the discovery of several first-in-class
candidates, coordinating both the biology disciplines with the chemistry resources (medicinal, analytical and structural chemistry) associated with the different projects.
- GM237354, antifungal inhibitors of mycotic protein synthesis (sordarins)
- GW844520, a novel Pyridone derivative with antimalarial activity
- Member of the team Falcipain project focusing on cysteine
- Member of the team GSK369796, a new aminoquinoline derivative with antimalarial activity
• As manager of therapeutic area, responsible for defining strategy, assessing projects and establishing
portfolio priorities, taking into account the commercial value and technical risk of individual projects.
• Deep experience in partnership agreements, joint ventures and in/out licensing with other companies
and leading public-private partnerships initiatives
- GSK invested its Sordarins (a novel class of antifungals) in Diversa Corporation: $8.5M Common Stock
- Collaboration agreement with Medicines for Malaria Venture
- Collaboration agreement with Global Alliance TB
• Experience working with regulatory agencies. Signer and responsible of 75 GSK drugs (preclinical
regulatory package) in front of the Spanish Agency of Medicines and Medical Products (AEMPS).
Contacts and meetings with FDA and EMA
1988-1990. Grant from the Spanish Ministry of Science and Technology Senior Scientist
• The objective of this grant was to reincorporate to Spain scientists who were working on relevant research projects in foreign countries
• Tuner the laboratory, including: buying equipment, recruiting scientists, and putting new molecular biology techniques in place

• Led a group of three people to study the mechanisms of transport through the cell envelope in Gram-
negative bacteria (University of Barcelona)
1987-1988. Uniformed Services University of the Health Sciences (USUHS) Associate Scientist
• Associate Scientist in the Department of Microbiology, of the Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Department of Defense. Bethesda, Maryland.
• Worked in the identification and characterization of genes involved in transport mechanisms through cellular envelopes in Gram-negative bacteria
1983-1987. University of Barcelona and Esteve laboratories Assistant professor University of Barcelona (1983-1985)
Principal investigator collaboration project between University of Barcelona and Esteve laboratories
• Member of the teaching team of the Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Barcelona
• Dedicated to the study of bacteriophages as therapeutic agents (University of Barcelona)
• Responsible for coordinating and conducting therapeutic efficacy studies using different experimental models of infection: systemic, skin, urinary tract infections. Project focused on improving the pharmacokinetic properties of the quinolone antibiotic class (collaboration project between University of Barcelona and Esteve laboratories)
• President of the Association for the discovery of novel antibiotics in Spain (Antibiotic, dedicated to promoting the discovery of novel antimicrobial agents
• Vice-President of the Spanish Network for the Development of Alternative Methods in Animal Experimentation (REMA)
• Member of the expert panel of Spanish Agency of Medicines and Medical Products (AEMPS)
• Member of the expert panel of Global Antibiotic R&D Partnership (GARDP)